Do analysts rate UDG or UPR?

Uniphar has a consensus price target of GBX 480, suggesting a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher possible upside, analysts clearly believe Uniphar is more favorable than UDG Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UDG Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Uniphar 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, UDG or UPR?

Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio UDG Healthcare £1.25B 0.00 N/A £25.40 N/A Uniphar £3.07B 0.30 £51.04M £19.50 18.51

Do analysts rate MGP or UPR?

Uniphar has a consensus price target of GBX 480, suggesting a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher possible upside, analysts plainly believe Uniphar is more favorable than Medica Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medica Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Uniphar 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, MGP or UPR?

Uniphar has higher revenue and earnings than Medica Group. Medica Group is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medica Group £76.98M 0.00 £7.20M £0.06 N/A Uniphar £3.07B 0.30 £51.04M £19.50 18.51

Is MGP or UPR more profitable?

Medica Group has a net margin of 9.35% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat Medica Group's return on equity. Company Net Margins Return on Equity Return on Assets Medica Group 9.35% 12.42% 6.62% Uniphar 1.66% 13.14% 3.76%

Do analysts recommend SBI or UPR?

Uniphar has a consensus price target of GBX 480, indicating a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher possible upside, analysts clearly believe Uniphar is more favorable than Sourcebio International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sourcebio International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Uniphar 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate UPR or OHGR?

Uniphar currently has a consensus target price of GBX 480, indicating a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher probable upside, equities analysts plainly believe Uniphar is more favorable than One Health Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Uniphar 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 One Health Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, UPR or OHGR?

Uniphar has higher revenue and earnings than One Health Group. Uniphar is trading at a lower price-to-earnings ratio than One Health Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Uniphar £3.07B 0.30 £51.04M £19.50 18.51 One Health Group £31.59M 1.29 N/A £14.98 20.03

Uniphar (UPR) Competitors

GBX 361 -4.76 (-1.30%)

As of 10:58 AM Eastern

Compare

UPR vs. UDG, SPI, MGP, SBI, and OHGR

Should you buy Uniphar stock or one of its competitors? Uniphar's main competitors and comparable companies include UDG Healthcare (UDG), Spire Healthcare Group (SPI), Medica Group (MGP), Sourcebio International (SBI), and One Health Group (OHGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Uniphar compare to UDG Healthcare?

UDG Healthcare (LON:UDG) and Uniphar (LON:UPR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, UDG Healthcare's average media sentiment score of 0.00 equaled Uniphar'saverage media sentiment score.

Company	Overall Sentiment
UDG Healthcare	Neutral
Uniphar	Neutral

Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UDG Healthcare	£1.25B	0.00	N/A	£25.40	N/A
Uniphar	£3.07B	0.30	£51.04M	£19.50	18.51

Uniphar has a net margin of 1.66% compared to UDG Healthcare's net margin of 0.00%. Uniphar's return on equity of 13.14% beat UDG Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UDG Healthcare	N/A	N/A	N/A
Uniphar	1.66%	13.14%	3.76%

36.9% of Uniphar shares are owned by institutional investors. 7.9% of Uniphar shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

UDG Healthcare pays an annual dividend of GBX 0.17 per share. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. UDG Healthcare pays out 0.7% of its earnings in the form of a dividend. Uniphar pays out 10.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Uniphar has a consensus price target of GBX 480, suggesting a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher possible upside, analysts clearly believe Uniphar is more favorable than UDG Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UDG Healthcare	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Uniphar	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Uniphar beats UDG Healthcare on 10 of the 13 factors compared between the two stocks.

How does Uniphar compare to Spire Healthcare Group?

Spire Healthcare Group (LON:SPI) and Uniphar (LON:UPR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Spire Healthcare Group has a beta of 0.933, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Uniphar has a beta of 1.102, indicating that its stock price is 10% more volatile than the broader market.

Uniphar has a net margin of 1.66% compared to Spire Healthcare Group's net margin of 1.04%. Uniphar's return on equity of 13.14% beat Spire Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spire Healthcare Group	1.04%	2.22%	3.73%
Uniphar	1.66%	13.14%	3.76%

In the previous week, Spire Healthcare Group had 2 more articles in the media than Uniphar. MarketBeat recorded 2 mentions for Spire Healthcare Group and 0 mentions for Uniphar. Spire Healthcare Group's average media sentiment score of 0.00 equaled Uniphar'saverage media sentiment score.

Company	Overall Sentiment
Spire Healthcare Group	Neutral
Uniphar	Neutral

21.8% of Spire Healthcare Group shares are owned by institutional investors. Comparatively, 36.9% of Uniphar shares are owned by institutional investors. 39.3% of Spire Healthcare Group shares are owned by company insiders. Comparatively, 7.9% of Uniphar shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spire Healthcare Group pays an annual dividend of GBX 2.30 per share and has a dividend yield of 1.0%. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Spire Healthcare Group pays out 57.5% of its earnings in the form of a dividend. Uniphar pays out 10.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Spire Healthcare Group currently has a consensus target price of GBX 245, suggesting a potential upside of 4.48%. Uniphar has a consensus target price of GBX 480, suggesting a potential upside of 32.96%. Given Uniphar's higher probable upside, analysts plainly believe Uniphar is more favorable than Spire Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spire Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Uniphar	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Uniphar has higher revenue and earnings than Spire Healthcare Group. Uniphar is trading at a lower price-to-earnings ratio than Spire Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spire Healthcare Group	£1.58B	0.59	£28.15M	£4.00	58.63
Uniphar	£3.07B	0.30	£51.04M	£19.50	18.51

Summary

Uniphar beats Spire Healthcare Group on 10 of the 15 factors compared between the two stocks.

How does Uniphar compare to Medica Group?

Medica Group (LON:MGP) and Uniphar (LON:UPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Uniphar has a consensus price target of GBX 480, suggesting a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher possible upside, analysts plainly believe Uniphar is more favorable than Medica Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medica Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Uniphar	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Medica Group has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Uniphar has a beta of 1.102, meaning that its stock price is 10% more volatile than the broader market.

Medica Group has a net margin of 9.35% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat Medica Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medica Group	9.35%	12.42%	6.62%
Uniphar	1.66%	13.14%	3.76%

Uniphar has higher revenue and earnings than Medica Group. Medica Group is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medica Group	£76.98M	0.00	£7.20M	£0.06	N/A
Uniphar	£3.07B	0.30	£51.04M	£19.50	18.51

In the previous week, Medica Group's average media sentiment score of 0.00 equaled Uniphar'saverage media sentiment score.

Company	Overall Sentiment
Medica Group	Neutral
Uniphar	Neutral

88.4% of Medica Group shares are owned by institutional investors. Comparatively, 36.9% of Uniphar shares are owned by institutional investors. 2.9% of Medica Group shares are owned by insiders. Comparatively, 7.9% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Medica Group pays an annual dividend of GBX 3 per share. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Medica Group pays out 5,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Uniphar pays out 10.1% of its earnings in the form of a dividend. Uniphar is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Uniphar beats Medica Group on 11 of the 15 factors compared between the two stocks.

How does Uniphar compare to Sourcebio International?

Sourcebio International (LON:SBI) and Uniphar (LON:UPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Uniphar has a consensus price target of GBX 480, indicating a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher possible upside, analysts clearly believe Uniphar is more favorable than Sourcebio International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sourcebio International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Uniphar	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Sourcebio International's average media sentiment score of 0.00 equaled Uniphar'saverage media sentiment score.

Company	Overall Sentiment
Sourcebio International	Neutral
Uniphar	Neutral

36.9% of Uniphar shares are owned by institutional investors. 7.9% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Uniphar has a net margin of 1.66% compared to Sourcebio International's net margin of 0.00%. Uniphar's return on equity of 13.14% beat Sourcebio International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sourcebio International	N/A	N/A	N/A
Uniphar	1.66%	13.14%	3.76%

Uniphar has higher revenue and earnings than Sourcebio International. Sourcebio International is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sourcebio International	£75.61M	0.00	N/A	£0.09	N/A
Uniphar	£3.07B	0.30	£51.04M	£19.50	18.51

Summary

Uniphar beats Sourcebio International on 10 of the 11 factors compared between the two stocks.

How does Uniphar compare to One Health Group?

Uniphar (LON:UPR) and One Health Group (LON:OHGR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Uniphar has a net margin of 1.66% compared to One Health Group's net margin of 0.00%. Uniphar's return on equity of 13.14% beat One Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Uniphar	1.66%	13.14%	3.76%
One Health Group	N/A	N/A	N/A

Uniphar currently has a consensus target price of GBX 480, indicating a potential upside of 32.96%. Given Uniphar's stronger consensus rating and higher probable upside, equities analysts plainly believe Uniphar is more favorable than One Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Uniphar	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
One Health Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Uniphar's average media sentiment score of 0.00 equaled One Health Group'saverage media sentiment score.

Company	Overall Sentiment
Uniphar	Neutral
One Health Group	Neutral

Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. One Health Group pays an annual dividend of GBX 6.23 per share and has a dividend yield of 2.1%. Uniphar pays out 10.1% of its earnings in the form of a dividend. One Health Group pays out 41.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Uniphar has higher revenue and earnings than One Health Group. Uniphar is trading at a lower price-to-earnings ratio than One Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Uniphar	£3.07B	0.30	£51.04M	£19.50	18.51
One Health Group	£31.59M	1.29	N/A	£14.98	20.03

36.9% of Uniphar shares are owned by institutional investors. Comparatively, 12.5% of One Health Group shares are owned by institutional investors. 7.9% of Uniphar shares are owned by insiders. Comparatively, 46.1% of One Health Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Uniphar beats One Health Group on 10 of the 14 factors compared between the two stocks.

Get Uniphar News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPR vs. The Competition

Export

Metric	Uniphar	Healthcare Providers & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£937.06M	£9.75B	£7.00B	£2.88B
Dividend Yield	0.48%	2.55%	2.57%	6.10%
P/E Ratio	18.51	34.73	271.41	368.46
Price / Sales	0.30	4.81	607.09	83,426.45
Price / Cash	9.97	24.81	28.87	27.89
Price / Book	2.83	5.24	11.09	7.08
Net Income	£51.04M	£311.06M	£3.45B	£5.89B
7 Day Performance	-0.25%	-0.20%	0.74%	0.54%
1 Month Performance	-6.72%	-0.40%	2.15%	3.02%
1 Year Performance	4.91%	18.66%	63.00%	64.50%

Uniphar Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPR Uniphar	N/A	GBX 361 -1.3%	GBX 480 +33.0%	+6.3%	£937.06M	£3.07B	18.51	3,000
UDG UDG Healthcare	N/A	N/A	N/A	N/A	£2.72B	£1.25B	42.48	9,000
SPI Spire Healthcare Group	0.6081 of 5 stars	GBX 234 +1.3%	GBX 245 +4.7%	+5.4%	£937.40M	£1.58B	58.50	420
MGP Medica Group	N/A	N/A	N/A	N/A	£259.85M	£76.98M	3,516.67	1,212
SBI Sourcebio International	N/A	N/A	N/A	N/A	£85.31M	£75.61M	1,277.78	194	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:UPR) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Uniphar (UPR) Competitors

UPR vs. UDG, SPI, MGP, SBI, and OHGR

How does Uniphar compare to UDG Healthcare?

Summary

How does Uniphar compare to Spire Healthcare Group?

Summary

How does Uniphar compare to Medica Group?

Summary

How does Uniphar compare to Sourcebio International?

Summary

How does Uniphar compare to One Health Group?

Summary

Media Sentiment Over Time

UPR vs. The Competition

Uniphar Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Uniphar (UPR) Competitors

UPR vs. UDG, SPI, MGP, SBI, and OHGR

How does Uniphar compare to UDG Healthcare?

Does the media refer more to UDG or UPR?

Which has stronger valuation and earnings, UDG or UPR?

Is UDG or UPR more profitable?

Do insiders and institutionals hold more shares of UDG or UPR?

Is UDG or UPR a better dividend stock?

Do analysts rate UDG or UPR?

Summary

How does Uniphar compare to Spire Healthcare Group?

Which has more volatility & risk, SPI or UPR?

Is SPI or UPR more profitable?

Does the media prefer SPI or UPR?

Do insiders and institutionals hold more shares of SPI or UPR?

Is SPI or UPR a better dividend stock?

Do analysts prefer SPI or UPR?

Which has stronger earnings & valuation, SPI or UPR?

Summary

How does Uniphar compare to Medica Group?

Do analysts rate MGP or UPR?

Which has more risk & volatility, MGP or UPR?

Is MGP or UPR more profitable?

Which has higher earnings and valuation, MGP or UPR?

Does the media refer more to MGP or UPR?

Do insiders & institutionals believe in MGP or UPR?

Is MGP or UPR a better dividend stock?

Summary

How does Uniphar compare to Sourcebio International?

Do analysts recommend SBI or UPR?

Does the media refer more to SBI or UPR?

Do insiders & institutionals believe in SBI or UPR?

Is SBI or UPR more profitable?

Which has better earnings and valuation, SBI or UPR?

Summary

How does Uniphar compare to One Health Group?

Is UPR or OHGR more profitable?

Do analysts rate UPR or OHGR?

Does the media favor UPR or OHGR?

Is UPR or OHGR a better dividend stock?

Which has higher valuation & earnings, UPR or OHGR?

Do insiders and institutionals hold more shares of UPR or OHGR?

Summary

Media Sentiment Over Time

UPR vs. The Competition

Uniphar Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools